Vote Scores

Home / Companies / Ascendis Pharma A/S / 30 May 2024

Meeting · year to 30 June 2024153 filers reporting

Ascendis Pharma A/S: meeting of 30 May 2024

Votes reported on Form N-PX, item by item

153 Form N-PX filers reported votes at the Ascendis Pharma A/S meeting of 30 May 2024. Their records fall into 8 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

2 nominees; 93.2% of reported votes for; 18 filers withheld from or voted against at least one nominee.

566 vote records from 149 filers. 10 of the 146 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

87.9% for6.0% against6.0% other6.8% against management149 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

2 vote records from 2 filers. 1 of the 2 filers that marked the item either way voted against management.

50.0% for50.0% against50.0% against management2 filers4.7% for95.3% against95.3% against management2,863 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

283 vote records from 149 filers. 2 of the 146 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

96.6% for0.7% against2.7% other1.4% against management149 filers99.9% for0.0% against0.0% other0.1% against management29,065,423 reported shares
4

SHAREHOLDER RIGHTS AND DEFENSESIssuer

SHAREHOLDER RIGHTS AND DEFENSES: management items

Management items in this category are shown together; filers word and number them differently.

30 vote records from 20 filers. 0 of the 19 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

100.0% for0.0% against0.0% against management20 filers100.0% for0.0% against0.0% against management6,892,331 reported shares, counted once per item in this group
5

CAPITAL STRUCTUREIssuer

CAPITAL STRUCTURE: management items

Management items in this category are shown together; filers word and number them differently.

810 vote records from 148 filers. 1 of the 145 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

97.3% for0.0% against2.7% other0.7% against management148 filers99.9% for0.1% against0.0% other0.1% against management84,825,977 reported shares, counted once per item in this group
6

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

254 vote records from 132 filers. 55 of the 129 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

56.1% for35.6% against8.3% other42.6% against management132 filers80.8% for15.4% against3.9% other19.2% against management22,197,758 reported shares, counted once per item in this group
7

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

815 vote records from 149 filers. 1 of the 146 filers that marked the item either way voted against management. 3 filers reported this item without a management mark.

97.3% for0.0% against2.7% other0.7% against management149 filers100.0% for0.0% against0.0% other0.0% against management84,901,078 reported shares, counted once per item in this group
8

OTHERIssuer

OTHER: management items

Management items in this category are shown together; filers word and number them differently.

62 vote records from 20 filers. 0 of the 20 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management20 filers100.0% for0.0% against0.0% against management4,440,382 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors3. Auditor
VanguardForFor
BlackRock and iSharesAgainst *For
FidelityForFor
State Street and SPDRForFor
American CenturyForFor
Franklin TempletonForFor
InvescoForFor
EquitableForFor
ProShares and ProFundsForFor
John Hancock and ManulifeForFor
Morgan Stanley, Eaton Vance and CalvertAgainst *For
Goldman SachsForFor
PGIM and PrudentialForFor
Jackson National fundsForFor
Northern Trust and FlexSharesForFor
SEIForFor
T. Rowe PriceForFor
ThriventForFor
Lincoln FinancialForFor
VoyaForFor
Russell InvestmentsForFor
NationwideForFor
Victory CapitalForFor
Brighthouse FundsForFor
Columbia ThreadneedleSplit or no voteFor
BNY MellonForFor
PrincipalForFor
Capital Group and American FundsForFor
Pacific Life fundsForFor
MFSForFor
TransamericaForFor
AllianceBernsteinForFor
Hartford FundsForFor
PIMCOForFor
AllspringForFor
MassMutualForFor
Harbor FundsAgainst *For
Janus HendersonForFor
Lord AbbettForFor
Artisan PartnersForFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Ascendis Pharma A/S meeting?

153 Form N-PX filers reported votes at the meeting of 30 May 2024. On say-on-pay, 1 of 2 voted against management (50.0%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Ascendis Pharma A/S on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Ascendis Pharma A/S

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Ascendis Pharma A/S with a meeting date within three days of 30 May 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.